SELLAS Life Sciences is a clinical-stage biopharmaceutical company developing immunotherapies and other oncology treatments. Its pipeline has centered on cancer vaccines and related approaches, including candidates such as galinpepimut-S (GPS) aimed at hematologic and solid tumors. The company seeks to stimulate targeted immune responses against tumor-associated antigens for patients with limited options after standard care. Without meaningful product revenue, its profile is that of a pure development-stage oncology biotech dependent on clinical and regulatory milestones.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -6.6 | — |
| Q3 2025 | 0 | — | -6.8 | — |
| Q4 2025 | 0 | — | -7.7 | — |
| Q1 2026 | 0 | — | -8.4 | — |
| Q2 2026 | 0 | — | -9.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Vera Therapeutics, Inc. (VERA), PENN Entertainment, Inc. (PENN), BioCryst Pharmaceuticals, Inc. (BCRX), City Holding Company (CHCO), Porch Group, Inc. (PRCH), Aehr Test Systems, Inc. (AEHR)